Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 2, 2008 - Issue
Submit an article Journal homepage
54
Views
3
CrossRef citations to date
0
Altmetric
Original Research

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Glen C MacDonald1 Viventia Biotech Inc., Winnipeg, Manitoba, Canada
,
Michèle Rasamoelisolo1 Viventia Biotech Inc., Winnipeg, Manitoba, Canada
,
Joycelyn Entwistle1 Viventia Biotech Inc., Winnipeg, Manitoba, Canada
,
Jeannick Cizeau1 Viventia Biotech Inc., Winnipeg, Manitoba, Canada
,
Denis Bosc1 Viventia Biotech Inc., Winnipeg, Manitoba, Canada
,
Wendy Cuthbert2 Viventia Biotech Inc., Mississauga, Ontario, Canada
,
Mark Kowalski2 Viventia Biotech Inc., Mississauga, Ontario, Canada
,
Maureen Spearman1 Viventia Biotech Inc., Winnipeg, Manitoba, CanadaCorrespondence[email protected]
&
Nick Glover2 Viventia Biotech Inc., Mississauga, Ontario, Canada
 show all
Pages 105-114 | Published online: 25 Jun 2008

Reprints and Permissions

Taylor & Francis does not sell reprints or permissions for this article. Please refer to the 'Licensing' tab on the article menu bar for information on the reuse conditions associated with this license type.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.